Protara Therapeutics (TARA), announced that patient dosing is now underway in its Phase 3 registrational THRIVE-3 clinical trial evaluating intravenous Choline Chloride in patients receiving long-term parenteral support. IV Choline Chloride, the Company’s investigational phospholipid substrate replacement therapy, was previously granted Fast Track designation by the U.S. Food and Drug Administration.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TARA:
- Protara Therapeutics initiated with an Overweight at Piper Sandler
- Regulatory De-Risking and Expanding Indications Drive Attractive Risk–Reward for Protara Therapeutics’ TARA-002
- Protara gets FDA Breakthrough Therapy and Fast Track Designations for TARA-002
- Protara Therapeutics Raises $86.3 Million in Offering
- Protara Therapeutics Completes $75 Million Stock Offering